Our current approaches to new antibacterial drug discovery integrate genetics, bioinformatics, functional genomics, and compound driven approaches to select targets for high throughput screening to identify new antibacterial leads.

The antiviral programs are focused on the discovery of new agents against HIV and Herpes virus. Our novel series of HIV protease inhibitors are active against all resistant virus and hold much promise as therapeutic agents. The herpesvirus research program is focused on finding inhibitors of the earliest steps of viral replication and also the prevention of reactivation from latency.

Infectious Deiseases is also investigating the role of bacterial and viral virulence factors in human disease and devising strategies for intervention. It is the mandate of our research to use the latest knowledge and technology to discover and develop therapeutic agents that offer advances in the treatment of infectious diseases.